Interestingly, in clinical practice, we witnessed a dramatic AFP decrease in end‐stage HCC patients, who were insensitive to conventional chemotherapy and targeted therapy after 3 to 4 courses of ATO pretreatment. The gene discussed is AFP; the disease is hepatocellular carcinoma.